Fumaric acid · people with chronic plaque psoriasis
It is very uncertain whether any systemic treatment changes fumaric acid compared with placebo (very low certainty).
1 finding from 1 review
Acitretin · people with chronic plaque psoriasis
It is very uncertain whether any systemic treatment changes acitretin compared with placebo (very low certainty).
2 findings from 1 review
Ixekizumab · people with chronic plaque psoriasis
Any systemic treatment probably leads to higher ixekizumab compared with placebo (moderate certainty).
2 findings from 1 review
Bimekizumab · people with chronic plaque psoriasis
Any systemic treatment showed no clear difference in bimekizumab compared with placebo (low certainty).
2 findings from 1 review
Risankizumab · people with chronic plaque psoriasis
Any systemic treatment probably leads to lower risankizumab compared with placebo (moderate certainty).
2 findings from 1 review
Ustekinumab · people with chronic plaque psoriasis
Any systemic treatment showed no clear difference in ustekinumab compared with placebo (moderate certainty).
2 findings from 1 review
Fumaric acid esters · people with chronic plaque psoriasis
It is very uncertain whether any systemic treatment changes fumaric acid esters compared with placebo (very low certainty).
1 finding from 1 review
Guselkumab · people with chronic plaque psoriasis
Any systemic treatment showed no clear difference in guselkumab compared with placebo (moderate certainty).
2 findings from 1 review
Adalimumab · people with chronic plaque psoriasis
Any systemic treatment showed no clear difference in adalimumab compared with placebo (moderate certainty).
2 findings from 1 review
Brodalumab · people with chronic plaque psoriasis
Any systemic treatment showed no clear difference in brodalumab compared with placebo (moderate certainty).
2 findings from 1 review
Secukinumab · people with chronic plaque psoriasis
Any systemic treatment showed no clear difference in secukinumab compared with placebo (moderate certainty).
2 findings from 1 review
Intervention not reported
Placebo · patients with moderate to severe eczema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Tezepelumab (1 RCT; 56 participants) · patients with moderate to severe eczema
The intervention showed no clear difference in tezepelumab (1 RCT; 56 participants) (low certainty).
1 finding from 1 review
Intervention not reported
Lebrikizumab (1 RCT; 156 participants) · patients with moderate to severe eczema
It is very uncertain whether the intervention changes lebrikizumab (1 RCT; 156 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
PF‐04965842 (1 RCT; 211 participants) · patients with moderate to severe eczema
It is very uncertain whether the intervention changes PF‐04965842 (1 RCT; 211 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
Tralokinumab (1 RCT; 153 participants) · patients with moderate to severe eczema
It is very uncertain whether the intervention changes tralokinumab (1 RCT; 153 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
Apremilast (1 RCT; 121 participants) · patients with moderate to severe eczema
The intervention showed no clear difference in apremilast (1 RCT; 121 participants) (low certainty).
1 finding from 1 review
Intervention not reported
Baricitinib (1 RCT; 75 participants) · patients with moderate to severe eczema
It is very uncertain whether the intervention changes baricitinib (1 RCT; 75 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
Placebo · patients with moderate to severe eczema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Total studies: 6 RCTsTotal participants: 1720 · patients with moderate to severe eczema
1 finding from 1 review